Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1

Yanik GA, Parisi MT, Naranjo A, Nadel H, Gelfand MJ, Park JR, Ladenstein RL, Poetschger U, Boubaker A, Valteau-Couanet D, Lambert B, Castellani MR, Bar-Sever Z, Oudoux A, Kaminska A, Kreissman SG, Shulkin BL, Matthay KK.

J Nucl Med. 2018 Mar;59(3):502-508. doi: 10.2967/jnumed.117.195883. Epub 2017 Sep 8. PMID: 28887399; PMCID: PMC5868501.

Previous
Previous

Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study

Next
Next

Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials